TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02917044

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Atrial Fibrillation Ablation
Description: Procedure involving catheter ablation to produce pulmonary vein isolation. Pulmonary veins are isolated by assessing electrograms circumferentially around the PV using the Orion catheter.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Catheters used to isolate pulmonary veins
Description: Catheters transiently inserted into body via femoral veins in order to produce pulmonary vein isolation. These catheters are the same in each arm and comprise the Orion catheter (Boston Scientific) and the Tacticath (St Jude) which are used to produce pulmonary vein isolation and which are approved for use in standard EP procedures by the relevant authorities (CE marked). It is merely the protocol by which they are used that iffers in the two arms.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Catheters used to isolate pulmonary veins
Description: Catheters transiently inserted into body via femoral veins in order to produce pulmonary vein isolation. These catheters are the same in each arm and comprise the Orion catheter (Boston Scientific) and the Tacticath (St Jude) which are used to produce pulmonary vein isolation and which are approved for use in standard EP procedures by the relevant authorities (CE marked). It is merely the protocol by which they are used that iffers in the two arms.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Atrial Fibrillation Ablation with HD mapping to isolate PVs
Description: Procedure involving catheter ablation to produce pulmonary vein isolation. Pulmonary veins are isolated by use of electroanatomical mapping with the Orion catheter around the sites ablation in order to target points of breakthrough.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rhythmia HD mapping
Description: Mapping activation patterns using the Rhythmia system in conjunction with the Orion catheter
Study: NCT00505167

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Memantine
Description: Patients randomized to receive either memantine or donepezil
Study: NCT04409535

Intervention type: OTHER
Intervention: WHOQOL-BREF survey
Description: Participants will be surveyed and interviewed about their perceptions regarding COVID-19 health emergency

Intervention type: OTHER
Intervention: WHOQOL-BREF survey
Description: Participants will be surveyed and interviewed about their perceptions regarding COVID-19 health emergency
Study: NCT00310206

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated Influenza A Vaccine A/H5N1
Description: Monovalent subvirion H5 vaccine (HA of A/Vietnam/1203/04), inactivated A/H5N1 vaccine administered intradermally (ID); doses: 3 or 9 micrograms.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated Influenza A Vaccine A/H5N1
Description: Monovalent subvirion H5 vaccine (HA of A/Vietnam/1203/04), inactivated A/H5N1 vaccine administered intradermally (ID); doses: 3 or 9 micrograms.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated Influenza A Vaccine A/H5N1
Description: Monovalent subvirion H5 vaccine (HA of A/Vietnam/1203/04), inactivated A/H5N1 vaccine administered intramuscularly (IM); doses: 15 or 45 micrograms.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated Influenza A Vaccine A/H5N1
Description: Monovalent subvirion H5 vaccine (HA of A/Vietnam/1203/04), inactivated A/H5N1 vaccine administered intramuscularly (IM); doses: 15 or 45 micrograms.
Study: NCT01644526

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hemoaccess Valve System
Description: Device that allows blood to selectively flow into an arteriovenous graft to provide vascular access for dialysis then turn off the flow of blood to the graft in between dialysis sessions.
Study: NCT00877955

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: alprazolam sublingual tablet commercial
Description: 0.5 mg sublingual tablet, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alprazolam sublingual tablet test
Description: 0.5 mg tablet, single dose
Study: NCT03185806

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Puncture and drainage
Description: The enrolled SAP patients are punctured under guidance of B ultrasound or CT scan, and prolonged drained by 8-F or 10-F pigtail tube
Study: NCT01338961

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hypothermic CPB
Description: Patients will be cooled to 31-32oC (nasopharyngeal) after the beginning of CPB. Rewarming will begin 10-15 min before release of aortic cross-clamp. The gradient between heat-exchanger and nasopharynx during rewarming will be maintained at 3oC. The rewarming will be stopped at 36,5oC
Study: NCT02762552

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial-holter monitoring
Description: Transcranial holter with an 4 hour-recording
Study: NCT02559791

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Reslizumab
Description: Reslizumab 3ml/kg once monthly for 4 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo once monthly for 2 months
Study: NCT00654875

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aliskiren
Description: Aliskiren supplied in 150 mg and 300 mg tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aliskiren
Description: Aliskiren supplied in 150 mg and 300 mg tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to Aliskiren
Description: Placebo to Aliskiren matching 150 and 300 mg tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to Aliskiren
Description: Placebo to Aliskiren matching 150 and 300 mg tablets
Study: NCT01801358

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AEB071
Description: Twice-daily doses of AEB071 for a cycle of 28-days, given without interruption (continuous cycles)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEK162
Description: Twice-daily doses of MEK162 for a cycle of 28-days, given without interruption (continuous cycles)
Study: NCT00505167

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Donepezil
Description: Patients randomized to receive either memantine or donepezil
Study: NCT01074749

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Accent Pacemaker
Description: Implantation of pacemaker
Study: NCT01801358

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEK162
Description: Twice-daily doses of MEK162 for a cycle of 28-days, given without interruption (continuous cycles)
Study: NCT02585271

Intervention type: DEVICE
Group type: OTHER
Intervention: Transanal decompression tube
Description: 22 Fr transanal decompression tube

Intervention type: DEVICE
Group type: OTHER
Intervention: Stent
Description: self-expandable colorectal nitinol alloys stent
Study: NCT01834716

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic vs. Non-Aerobic exercise

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic vs. Non-Aerobic exercise
Study: NCT01930344

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 3D Laparoscopic visual system
Description: Three-dimensional endoscope used for surgery - multiple company products - and passive polarising three-dimensional laparoscopic displays;

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: 2D Laparoscopic visual system
Description: Standard 2D HD Laparoscopic Visual System
Study: NCT04257162

Intervention type: OTHER
Group type: OTHER
Intervention: Tumor and Blood sample collection
Description: This is a non-interventional protocol and does not provide study drug or specific requirements for how the patients should be treated.~Nevertheless, patients participating in T-DXd trials included in this study are those who were randomized to receive T-DXd.~Tumor sample and blood sample will be collected within the framework of HER2-Predict Study
Study: NCT00583882

Intervention type: OTHER
Group type: OTHER
Intervention: Routine change of central venous catheters
Description: Changeing CVCs on a regular basis to decrease infection rate.

Intervention type: OTHER
Group type: OTHER
Intervention: Routine change of central venous catheters
Description: Changeing CVCs on a regular basis to decrease infection rate.

Intervention type: OTHER
Group type: OTHER
Intervention: Routine change of central venous catheters
Description: Changeing CVCs on a regular basis to decrease infection rate.
Study: NCT04530591

Intervention type: OTHER
Intervention: Survey
Description: Participants will complete a survey about their opioid use history, its impact on their lives, their current strategies for preventing or reversing opioid overdoses, and their preferences for a device-based intervention.

Intervention type: OTHER
Intervention: Interview
Description: Participants will participate in a semi-structured interview, during which they will provide feedback on non-functional, looks-like prototypes of a naloxone delivery device.
Study: NCT00093418

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tipifarnib
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tipifarnib
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tipifarnib
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tipifarnib
Description: Given orally
Study: NCT00058084

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ixabepilone
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mitoxantrone hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: Given orally
Study: NCT02750007

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HS-20004
Study: NCT00003910

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Patients not responding to MTX after 4 months received Cy orally at 100 mg daily in step two with the same prednisone schedule. In patients showing a partial response, but not a CR, the maximum period of therapy was 1 year.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Initial treatment consisted of MTX given orally at 10 mg/m2 in divided doses once weekly.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone was given orally at 1 mg/kg per day for 30 days and then tapered off in the subsequent 24 days.
Study: NCT00697034

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capsaicin
Description: natural alkaloid derived from hot chili peppers and activates vanilloid receptors that are also activated by endogenous cannabinoid anandamide applied three times daily
Study: NCT05475587

Intervention type: OTHER
Intervention: Routine care
Description: Both two groups received the same routine care.

Intervention type: OTHER
Intervention: Routine care
Description: Both two groups received the same routine care.
Study: NCT03333902

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: QLB
Description: QLB, quadratus lumborum block.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: QLB
Description: QLB, quadratus lumborum block.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: QLB
Description: QLB, quadratus lumborum block.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: QLB
Description: QLB, quadratus lumborum block.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intravenous patient controlled analgesia (PCA)
Description: Intravenous patient controlled analgesia (PCA) pump was used to supply additional analgesia and removed 48 h post-operationally.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intravenous patient controlled analgesia (PCA)
Description: Intravenous patient controlled analgesia (PCA) pump was used to supply additional analgesia and removed 48 h post-operationally.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intravenous patient controlled analgesia (PCA)
Description: Intravenous patient controlled analgesia (PCA) pump was used to supply additional analgesia and removed 48 h post-operationally.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous patient controlled analgesia (PCA)
Description: Intravenous patient controlled analgesia (PCA) pump was used to supply additional analgesia and removed 48 h post-operationally.
Study: NCT02681757

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: triple antibiotic ointment dressing
Description: used for control group under soft cast

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mepitel Ag
Description: used for variable/experimental group under soft cast
Study: NCT04339803

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: rehabilitation intervention
Description: we use lower limb mirror therapy after stroke for two weeks
Study: NCT02634034

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A: NK-104-CR 8 mg
Description: NK-104-CR 8 mg (Controlled Release single 8-mg tablet)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A: NK-104-CR 8 mg
Description: NK-104-CR 8 mg (Controlled Release single 8-mg tablet)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A: NK-104-CR 8 mg
Description: NK-104-CR 8 mg (Controlled Release single 8-mg tablet)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B: Pitavastatin IR 4 mg
Description: Pitavastatin IR 4 mg (Immediate Release single 4-mg tablet)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B: Pitavastatin IR 4 mg
Description: Pitavastatin IR 4 mg (Immediate Release single 4-mg tablet)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B: Pitavastatin IR 4 mg
Description: Pitavastatin IR 4 mg (Immediate Release single 4-mg tablet)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: C: Pitavastatin IR 8 mg
Description: Pitavastatin IR 8 mg (Immediate Release two 4-mg tablets)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: C: Pitavastatin IR 8 mg
Description: Pitavastatin IR 8 mg (Immediate Release two 4-mg tablets)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: C: Pitavastatin IR 8 mg
Description: Pitavastatin IR 8 mg (Immediate Release two 4-mg tablets)
Study: NCT00493233

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2 antipsychotic medications (combinations of olanzapine, risperidone, clozapine, seroquel, haldol, perphenazine)
Description: Primary antipsychotic medication (olanzapine, oral risperidone, seroquel, clozapine, haldol, perphenazine) will be determined by the treating physician and participants will continue taking the concomitant antipsychotic drug. The dose of the main antipsychotic drug will remain open and flexible at the discretion of the attending physician. The dose of the second antipsychotic drug will remain fixed throughout the study period.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: main antipsychotic medication and placebo
Description: The main antipsychotic drug will be determined by the treating physician. Participants will be allocated to placebo in place of the concomitant antipsychotic drug. The dose of the main antipsychotic drug will remain open and flexible at the discretion of the attending physician.
Study: NCT01760746

Intervention type: OTHER
Intervention: Injection of Avastin / Lucentis, sampling aqueous humour
Description: Study participants will be divided into two arms. Subjects will receive Avastin or Lucentis a few days before vitrectomy surgery. The assignment will be double-masked.The first sample of aqueous humor will be obtained immediately prior to the intravitreal injection.~On the same of the intravitreal injection, a blood sample will be taken for hemoglobin A1C measurement. Approximately 1 week later when patients are having their scheduled vitrectomy surgery, an additional sample of aqueous humour will be obtained .~Intraocular cytokines levels will be measured in aqueous humor samples using multiplex cytokine assays.
Study: NCT03663777

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Isometric handgrip training
Description: Intervention period will last 12 weeks. Experimental group will perform three sessions per week of home-based handgrip exercise. The exercise protocol will consist of eight sets of bilateral handgrip contraction of two minutes of isometric contraction, with 30% of maximum voluntary contraction, and two minutes of interval between sets. Patients will receive a diary to record the sessions and report difficulties during the training. The patients be recommended to increase daily physical activity levels, and weekly, there will be phone contacts with the patients to reinforce the exercise recommendations.

Intervention type: OTHER
Group type: OTHER
Intervention: Control Group
Description: Intervention period will last 12 weeks. Patients will be recommended to increase daily physical activity levels, and weekly, there will be phone contacts to reinforce the recommendations.
Study: NCT01513811

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Polyethylene glycol electrolyte solutions
Description: Patients received 2 packets of polyethylene glycol electrolyte solutions(PEG-E) without itopride.PEG-E was dissolved in 2 L of water. Patients were instructed to drink PEG solution 200ml every 10 min consumed the total 2 L solution in 2 hours.6 hours later, the colonoscopy was performed.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Itopride and Polyethylene glycol electrolyte solutions
Description: Patients were assigned to itopride 150mg, then 30 min later they were given 2 packets of polyethylene glycol electrolyte solutions(PEG-E). PEG-E was dissolved in 2 L of water. Patients were instructed to drink PEG solution 200ml every 10 min consumed the total 2 L solution in 2 hours. 6 hours later, the colonoscopy was performed.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: itopride and polyethylene glycol electrolyte solutions
Description: Patients received itopride 150mg t.i.d(7am、12am、8pm) 24 hours before the examination day and another 150mg 30min before administration of polyethylene glycol electrolyte solutions(PEG-E).Two packets of PEG-E were dissolved in 2 L of water. Patients were instructed to drink PEG solution 200ml every 10 min and consumed the total 2 L solution in 2 hours. 6 hours later, the colonoscopies were performed.
Study: NCT00881439

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aliskiren
Description: Oral, 300 mg, once daily, 6 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching Placebo once daily, 6 months
Study: NCT00176436

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Diet support group
Description: Diet support group weekly and exercise sessions 3 times/week, placebo medication

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Group counseling and exercise
Description: Support group weekly and exercise sessions 3 times/week for 24 weeks
Study: NCT01468753

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Vaginal Insemination
Description: Women will perform vaginal insemination during the fertile period with semen within one hour of collection. Vaginal insemination will occur within one hour of collection 2 days prior to ovulation, on the day of ovulation and 2 days after ovulation for up to 6 months or until conception occurs. For example, if ovulation were on day 14 of a 28 day menstrual cycle, vaginal insemination will occur on days 12, 14 and 16 of the cycle.
Study: NCT03578016

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Circle of Security-Parenting
Description: COS-P is a brief, behavioral and insight oriented therapeutic group approach for parents with the aim to promote parental sensitivity and attachment and autonomy in the parent-child relationship. The parents will participate in ten weekly 1,5-hour sessions at the clinic conducted by two COS-certified therapists. Groups will include 4-5 families at a time.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment as Usual
Description: TAU consists of clinical assessment and treatment.

Intervention type: OTHER
Group type: OTHER
Intervention: Treatment as Usual
Description: TAU consists of clinical assessment and treatment.
Study: NCT04048759

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Remote Low
Description: Participants will attend 40 min remotely delivered group MVPA sessions once a week, receive a step counter, access to resources for increasing MVPA, and one 20-min remotely delivered individual support/education session/wk.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Remote High
Description: Participants will attend 40 min remotely delivered group MVPA sessions 3x a week, receive a step counter, access to resources for increasing MVPA, and one 20-min remotely delivered individual support/education session/wk.
Study: NCT02663752

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Bone marrow aspirate
Description: Patients experiencing a hematological response and patients not experiencing a hematological response while on deferasirox treatment received a new bone marrow aspirate in order to investigate the presence of differential gene expression between those two groups

Intervention type: DRUG
Group type: OTHER
Intervention: Deferasirox
Description: Patients are already on commercial deferasirox before entering the study.
Study: NCT03841539

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mediterranean Diet
Description: Diet consisting of fruits, vegetables, whole grains, low-fat dairy, olive oil, seafood, nuts and beans. It is low in red and processed meats, solid fats and added sugars.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Study Supplement
Description: Randomized to take a daily dose of either 2 grams of Omega 3 fatty acids or 2 grams of a Placebo.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Study Supplement
Description: Randomized to take a daily dose of either 2 grams of Omega 3 fatty acids or 2 grams of a Placebo.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Low-fat Diet
Description: Diet consisting of fruits, vegetables, whole grains, low-fat dairy, and low-fat protein, with fat contributing no more than 25% of calories.
Study: NCT01605032

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous Hematopoietic Stem Cell Transplantation
Description: Undergo autologous PBSCT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral Blood Stem Cell Transplantation
Description: Undergo autologous PBSCT
Study: NCT03097055

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Traditional Acupuncture
Description: widely ongoing traditional acupoints in scalp and limbs with traditional deqi manipulation, for stroke patient

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Minimal Acupuncture
Description: non-traditional acupoints in scalp and limbs, with minimal manipulation